What we can learn from ventures into biotech?

The pharmaceutical industry is undergoing considerable changes in face of R&D diminished productivity, the patent cliff and increased competitiveness leading to pricing pressure.

The traditional linear approach to corporate innovation appears unable to increase pipeline value and corporate revenue. In fact, recent mergers and acquisitions, geographic expansion and diversification into consumer and animal healthcare have neither compensated for the slowdown in innovation, nor decreased the unsustainable cost of bringing new drugs to the market.

Big pharma, as a result, is moving…